Therapeutic Antibodies

Human antibodies
#Antibodies #Antibody discovery workflow #Antibody-based therapeutics #Monoclonal antibodies #Therapeutic Antibodies

Opportunity in the antibody market: Hear from the experts

Join DDW for this free event ‘Where is the opportunity in the therapeutic antibody market?’, which is co-sponsored by Bio-Rad and Benchling. The event will take place on 30 April at 3PM BST / 4pm CEST / 10am EDT / 7am PDT. Read More

Webinar date:
Co-sponsored by Benching and Bio-Rad
#News

#Drug discovery #Therapeutic Antibodies

ebook: Drug discovery and the impact of mAbs

This eBook sponsored by Thermo Fisher Scientific explores the impact of monoclonal antibodies (mAbs) on the treatment of cancer, autoimmune and infectious diseases, and inflammatory conditions, as well as the latest clinical research and where the innovation in mAb development might be in the future. Download this exclusive eBook… Read More

#DDW eBooks

Monoclonal antibodies
#Antibodies #Antibody discovery workflow #Antibody-based therapeutics #Monoclonal antibodies #Therapeutic Antibodies

Webinar: How can we develop better therapeutic antibodies?

Join DDW for this free event ‘Where is the opportunity in the therapeutic antibody market?’, which is co-sponsored by Bio-Rad and Benchling. The event will take place on 30 April at 3PM BST / 4pm CEST / 10am EDT / 7am PDT. Read More

Webinar date:
Co-sponsored by Benching and Bio-Rad
#News

#Antibodies #Cancer research #Oncology #Phase III trial #Therapeutic Antibodies

Improving the standard of care: Inside the DUO-E trial

Professor Shannon Westin is principal investigator of the DUO-E trial, here she speaks to DDW’s Megan Thomas about why the standard of care needs improving and the impact of therapeutic antibodies such as durvalumab. The DUO-E trial is a three-arm, randomised, double-blind, placebo-controlled, multicentre Phase III trial assessing the combination… Read More

#Cancer Research #Exclusive Content

Antibodies
#Antibodies #Antibody discovery workflow #Antibody-based therapeutics #Monoclonal antibodies #Therapeutic Antibodies

Webinar: Innovations and opportunities in the therapeutic antibody market

Join DDW for this free event ‘Where is the opportunity in the therapeutic antibody market?’, which is co-sponsored by Bio-Rad and Benchling. The event will take place on 30 April at 3PM BST / 4pm CEST / 10am EDT / 7am PDT. Read More

Webinar date:
Co-sponsored by Benching and Bio-Rad
#News

#Alzheimer's #Antibodies #Monoclonal antibodies #Neurodegenerative disorders #Therapeutic Antibodies

Therapeutic antibodies in the fight against Alzheimer’s

ImmunoBrain Checkpoint (IBC) is currently dosing patients in a clinical trial with its monoclonal antibody for Alzheimer’s disease (AD). DDW’s Megan Thomas caught up with Professor Michal Schwartz to learn more about her work and the work being carried out by IBC. MT: Can you provide an overview of your… Read More

#Exclusive Content

#Antibodies #Antibody discovery workflow #Antibody-based therapeutics #Monoclonal antibodies #Therapeutic Antibodies

Where is the opportunity in the therapeutic antibody market?

Join DDW for this free event ‘Where is the opportunity in the therapeutic antibody market?’, which is co-sponsored by Bio-Rad and Benchling. The event will take place on 30 April at 3PM BST / 4pm CEST / 10am EDT / 7am PDT. Read More

Webinar date:
Co-sponsored by Benching and Bio-Rad
#News

#Therapeutic Antibodies

App Note: Biologics developability: How Merck creates developability profiles for their mAbs with Prometheus Panta

In this Application Note, discover how the Protein Sciences group at Merck & Co. builds developability profiles for their monoclonal antibody variants.   Get an in-depth explanation of the experiments they set up to obtain parameters that help them decide which candidates have the best potential to reach the market, and how they… Read More

#App Notes

#Antibodies #Antibody discovery workflow #Therapeutic Antibodies #Twist Bioscience

Every day matters

This paid-for advertorial by Twist Bioscience appeared in the Therapeutic Antibodies Guide – DDW Volume 25 – Issue 1, Winter 2023/2024 Improving gene synthesis speed can reduce workflow times, saving you invaluable time, says Twist Bioscience. Time can mean more than money when you’re studying a deadly pathogen. The importance of speed and… Read More

#Exclusive Content

View from the International Space Station
#Antibodies #BioOrbit #Manufacturing #Start-ups #Therapeutic Antibodies

Why Carol Vorderman’s daughter is taking antibodies into space

A UK-based start-up is developing technology to build a pharmaceuticals factory in space that will make antibody treatments more accessible and easier to administer. BioOrbit is aiming to build the first pharmaceuticals factory in microgravity and are currently developing a platform for large-scale crystallisation of protein… Read More

#Editor's Choice #News #Start-up Zone

Robot holds up a pill
#AI / data analytics / healthtech / informatics #Cancer research #Cell Science #Immunotherapy #Singapore #SLAS2024 #Therapeutic Antibodies

Read the Winter issue of DDW now

The Winter issue of Drug Discovery World (DDW) is out now and asks whether AI can deliver better immunotherapies for cancer and includes expert predictions on what to expect from the sector in 2024, alongside a supplement looking at SLAS2024 and an exclusive guide exploring therapeutic antibodies. Read More

#News

#Therapeutic Antibodies

Guide: Therapeutic Antibodies Guide Twist

DDW has published the latest edition in its guide series ‘The global innovation and opportunity in therapeutic antibody development’.   The DDW Therapeutic Antibodies Guide looks at the trajectory of antibody therapies in 2024 and use-cases across disease areas.  Download to learn about:   Therapeutic antibody potential in 2024  Therapeutic antibodies… Read More

#DDW Guides

#Arxx Therapeutic #Calluna Pharma #Funding #Immune system #Monoclonal antibodies #Oxitope Pharm #Therapeutic Antibodies

Calluna Pharma announces €75 million Series A financing 

Oxitope Pharma and Arxx Therapeutics, companies with a shared goal of leveraging the innate immune system to discover and develop disease modulating therapies, has announced their merger to form Calluna Pharma.   Calluna has raised €75 million in a series A financing and is backed by Oxitope and Arxx’s existing… Read More

#Business & Investment #News

#Drug development #Drug discovery #Guide #Therapeutic Antibodies

DDW Therapeutic Antibody Guide 2024

Download the exclusive Guide and read about: The global innovation in therapeutic antibody development and the opportunities being created What does the therapeutic antibody sector need to overcome challenges and get to market faster? Industry insight and forecasts… Read More

#DDW eBooks #DDW Guides

Antibodies
#Antibodies #Antibody discovery workflow #Antibody drug conjugate (ADC) #CAR-T #Therapeutic Antibodies

Fortis Life Sciences leads the way in custom antibody discovery

This article is sponsored by Fortis Life Sciences. In the ever-evolving landscape of therapeutic development, the role of antibodies has become increasingly apparent. Antibodies are used as therapeutics, components of therapeutics such as antibody-drug conjugates (ADC) and CAR-T cells, and as companion diagnostic tools. Fortis Life Sciences offers… Read More

#News